# Dana-Farber Cancer Institute account plan

> Dana-Farber Cancer Institute is a Boston not-for-profit cancer research and treatment center with FY2025 operating revenues of $3,922,850 thousand.

## At a glance

Dana-Farber Cancer Institute is a comprehensive cancer center for basic and clinical cancer research and treatment, a Massachusetts not-for-profit 501(c)(3) that primarily serves patients in the New England region. It earns revenue from patient care, research (grants, contracts, licenses and research gifts) and philanthropy; its inpatient hospital currently sits inside Brigham & Women's Hospital. In FY2025 (year ended September 30, 2025) total operating revenues were $3,922,850 thousand against $3,438,436 thousand in FY2024, with operating income of $102,353 thousand. It is building its own 300-bed cancer hospital in the Longwood Medical Area. Benjamin L. Ebert is President and CEO.

## Business units

- **Patient care** (about 77% of FY2025 operating revenues ($3,012,853 thousand)): Outpatient and inpatient cancer care, with inpatient care delivered inside Brigham & Women's Hospital. Net patient service revenue rose from $2,593,981 thousand in FY2024; Medicare was 37% of the payor mix and HMO, commercial and other 36%.
- **Research** (about 18% of FY2025 operating revenues ($706,681 thousand)): Basic and clinical cancer research funded by federal grants ($229,899 thousand), non-federal grants ($231,733 thousand), gifts and licenses and royalties. Federal award expenditures were $230,341,899, mostly from HHS/NIH.
- **Philanthropy** (about 4% of FY2025 operating revenues ($147,239 thousand)): Unrestricted contributions and bequests; total contributions received and pledged were $314,121 thousand, of which the Jimmy Fund raised $117,696 thousand.
- **Other operating revenues** (about 1% of FY2025 operating revenues ($56,077 thousand)): Management services, rent, royalties and ancillary services such as parking, cafeteria and gift shop.

## Strategic priorities

- **New 300-bed cancer hospital**: A 300-bed cancer hospital in the Longwood Medical Area, owned and operated by Dana-Farber, received final Massachusetts DPH approval on May 19, 2025; its debt financing is expected in 2026.
- **Clinical collaboration with BIDMC**: The hospital is central to a clinical collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians for adult cancer patients.
- **Protect research funding**: About one-third of research funding comes from the federal government; the CEO has been engaging Congress, citing bipartisan support for cancer research.
- **AI in care and research**: AI is to take care of administrative tasks, improve diagnostic accuracy in radiology and pathology, and transform translational research with large language models.
- **Scientific bets**: Early detection and interception, drugs against "undruggable" targets such as KRAS, and extra support for rare and pediatric cancers.

## Investments and deals

- **Hospital construction**: Additions to property, plant and equipment were $165,584 thousand in FY2025 and construction-in-progress rose to $206,229 thousand.
- **Hospital financing hedges**: Swaptions with notional amounts of $1,191,644 thousand with JPMorgan and $611,094 thousand with Goldman Sachs hedge the anticipated hospital debt financing.
- **Global oncology**: Dana-Farber Global Oncology is the entity through which the Institute is engaging in work in China.

## Challenges and risks

- **Federal research funding uncertainty**: Federal funding freezes hit Harvard University and Harvard Medical School; Dana-Farber says it had suffered no cuts but is preparing for various scenarios.
- **Complex reimbursement rules**: Medicare and Medicaid rules are complex and subject to interpretation, so recorded estimates may change by a material amount.
- **Interest rate and investment risk**: Variable-rate bonds, swaps and swaptions carry interest rate risk, and $1,759,967 thousand sits in non-marketable hedge and private equity funds.
- **Grant competition**: Less than 10 percent of the grants Dana-Farber submits to the National Cancer Institute are funded.

## What leadership says

> "The promise that AI can accelerate the development of new cancer drugs and accelerate scientific research broadly is absolutely thrilling." — Benjamin L. Ebert, President and CEO, The ASCO Post interview, March 25, 2026

> "AI in oncology isn't a way of replacing humans. It's a way of taking care of some of the administrative tasks that allow us to have more human interactions with our patients." — Benjamin L. Ebert, President and CEO, The ASCO Post interview, March 25, 2026

> "I'm an absolute believer that this is the most promising time for cancer research and for new therapeutics for cancer that we've ever had." — Benjamin Ebert, President and CEO, Walker Webcast, April 30, 2025


## Where a supplier can help

- **New hospital fit-out**: The 300-bed Longwood hospital, with construction-in-progress already rising, creates demand for medical equipment, IT infrastructure and facility services.
- **AI for radiology, pathology and admin**: The CEO's AI priorities (administrative tasks, diagnostic accuracy, large language models in translational research) fit clinical AI and data platform vendors.
- **Research operations and grants management**: With research funded by federal grants, non-federal grants and gifts, and federal funding uncertain, grant management and research administration tools can help.
- **Clinical trial partnerships**: Pharma and biotech fund part of the research through clinical trials, which suits trial sponsors and clinical research service providers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Dana-Farber Cancer Institute, Inc. and Subsidiaries - Audited Consolidated Financial Statements and Uniform Guidance Reports, Year ended September 30, 2025](https://app.fac.gov/dissemination/report/pdf/2025-09-GSAFAC-0000421108)

Annual report · 2026-01-21

- Dana-Farber Cancer Institute, Inc. is a comprehensive cancer center for basic and clinical cancer research and treatment, a Massachusetts not-for-profit 501(c)(3) that primarily serves patients in the New England region; its inpatient hospital currently sits inside Brigham & Women's Hospital.
- FY2025 (year ended September 30, 2025) total operating revenues were $3,922,850 thousand vs $3,438,436 thousand in FY2024; net patient service revenue $3,012,853 thousand (FY2024: $2,593,981 thousand), research revenues $706,681 thousand.
- Operating income was $102,353 thousand (FY2024: $87,031 thousand); with $236,617 thousand of non-operating gains the excess of revenues over expenses reached $338,970 thousand.
- Balance sheet: total assets $5,994,076 thousand, investments $3,554,754 thousand, total net assets $4,485,156 thousand, long-term debt and finance leases $537,541 thousand before current portion; three $100,000 thousand credit lines undrawn.
- Payor mix of patient revenue: Medicare 37%, HMO/commercial/other 36%, Blue Cross 22%, Medicaid 4%, self-pay 1%.
- Research is funded by federal grants ($229,899 thousand), non-federal grants ($231,733 thousand), gifts ($205,873 thousand) and licenses/royalties ($39,176 thousand); total federal award expenditures were $230,341,899, mostly HHS/NIH.
- Strategy: a 300-bed cancer inpatient hospital in the Longwood Medical Area, owned and operated by Dana-Farber, approved by the Massachusetts DPH on May 19, 2025, central to a clinical collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians; its debt financing is expected in 2026 and is hedged with swaptions (notional $1,191,644 thousand with JPMorgan and $611,094 thousand with Goldman Sachs).
- Capex: additions to property, plant and equipment $165,584 thousand in FY2025; construction-in-progress rose to $206,229 thousand.
- Clean audit by KPMG (report dated January 21, 2026): unmodified opinion, no material weaknesses, no findings, low-risk auditee.
- Risks named: complex Medicare/Medicaid regulation and possible government review, non-marketable alternative investments ($1,759,967 thousand in hedge and private equity funds), interest-rate risk on variable-rate debt and swaptions, malpractice and litigation.

### [In Celebration of a Decades-Long Journey of Discovery and Innovation (The ASCO Post interview with Benjamin L. Ebert)](https://ascopost.com/issues/march-25-2026/in-celebration-of-a-decades-long-journey-of-discovery-and-innovation/)

Executive talk · Benjamin L. Ebert, President and CEO · 2026-03-25

- Benjamin L. Ebert, MD, PhD, marked one year as President and CEO of Dana-Farber Cancer Institute; he also directs Dana-Farber/Harvard Cancer Center and chaired Medical Oncology at Dana-Farber from 2017 to 2024.
- The interviewer frames the period around Dana-Farber's new collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians.
- On federal research funding: he has been "spending a bit of time in Washington" and is impressed by "the bipartisan support there is for biomedical research, particularly in cancer research."
- He welcomes Dana-Farber's Anthony Letai becoming the 18th Director of the National Cancer Institute on September 29, 2025.
- On AI: it takes care of administrative tasks, will improve diagnostic accuracy in radiology and pathology, and can transform translational research with large language models; "The promise that AI can accelerate the development of new cancer drugs and accelerate scientific research broadly is absolutely thrilling."
- His science background: myelodysplastic syndromes, clonal hematopoiesis and the mechanism of lenalidomide, which fed the field of targeted protein degradation.
- Leadership focus as chair and now CEO: hiring collaborative people and cultivating the right environment for discovery and clinical medicine.

### [Walker Webcast: Rewriting the Rules of Medicine with Dr. Ben Ebert, President and CEO of Dana-Farber Cancer Institute](https://walkerdunlop.com/webcast/dr-ben-ebert)

Podcast · Benjamin Ebert, President and CEO · 2025-04-30

- Benjamin Ebert, President and CEO of Dana-Farber, on the Walker Webcast with Willy Walker (April 30, 2025).
- Dana-Farber is building its own inpatient hospital of 300 beds, capped in height by a nearby park on the Muddy River.
- Budget: "$3 billion budget, $3.5 billion budget? Much of that is the clinical budget"; research funding is about one-third federal (NIH/NCI), a little more than a third philanthropy, the rest private sector (pharma, biotech, venture).
- At the National Cancer Institute "less than 10 percent of the grants that we submit are actually funded"; philanthropy lets projects start quickly.
- Federal freezes had hit Harvard University and Harvard Medical School but not the affiliate hospitals; Dana-Farber has "independent governance and independent finances" and had suffered no cuts to date while preparing for scenarios.
- The Pan-Mass Challenge raised $75 million last year; 6,000-7,000 riders.
- Talent: culture and the Boston ecosystem attract recruits more than pay; collaboration through Break Through Cancer with MD Anderson, Memorial Sloan Kettering, MIT and Johns Hopkins.
- Bets: AI (AlphaFold, AI in radiology and pathology), early detection and interception (blood biopsies), drugs against "undruggable" targets such as KRAS, and over-allocation to rare and pediatric cancers.

## Questions about Dana-Farber Cancer Institute

### What does Dana-Farber Cancer Institute do?

It is a comprehensive cancer center in Boston dedicated to basic and clinical cancer research and treatment, primarily serving patients in New England.

### What is Dana-Farber's revenue?

Total operating revenues were $3,922,850 thousand in FY2025 (year ended September 30, 2025), of which net patient service revenue was $3,012,853 thousand.

### Who leads Dana-Farber?

Benjamin L. Ebert, MD, PhD, is President and CEO; he also directs Dana-Farber/Harvard Cancer Center.

### What is Dana-Farber's strategy?

Building its own 300-bed cancer hospital in the Longwood Medical Area as part of a clinical collaboration with Beth Israel Deaconess Medical Center, while investing in AI, early detection and new therapies.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
